• LAST PRICE
    0.0250
  • TODAY'S CHANGE (%)
    Trending Down-0.0015 (-5.6604%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0250 / 0.0265
  • Day Range
    Low 0.0250
    High 0.0250
  • 52 Week Range
    Low 0.0190
    High 0.1150
  • Volume
    1,500
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.0265
TimeVolumeMYMX
11:25 ET10000.025
12:55 ET5000.025
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMYMX
Mymetics Corp
8.0M
-1.4x
---
United StatesNAVB
Navidea Biopharmaceuticals Inc
8.6M
-0.5x
---
United StatesNSTM
Novelstem International Corp
8.4M
0.7x
---
United StatesLMNL
Liminal BioSciences Inc
12.3M
-0.6x
---
United StatesFRTX
Fresh Tracks Therapeutics Inc
7.4M
-0.3x
---
United StatesXCUR
Exicure Inc
6.9M
-0.1x
---
As of 2023-01-26

Company Information

Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.

Contact Information

Headquarters
Route De La Corniche 4EPALINGES, Switzerland 1066
Phone
---
Fax
---

Executives

President, Chief Executive Officer, Chief Financial Officer
Ronald Kempers
Chief Scientific Officer
Sylvain Fleury
Director
Ulrich Burkhard
Independent Director
Marcel Ruegg
Independent Director
Thomas Staehelin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$8.0M
Revenue (TTM)
$1.1M
Shares Outstanding
303.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.26
EPS
$-0.02
Book Value
$-0.22
P/E Ratio
-1.4x
Price/Sales (TTM)
7.6
Price/Cash Flow (TTM)
---
Operating Margin
-156.88%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.